Publicado

2022-02-04

Sistema endocannabinoide y cannabidiol en el manejo del dolor en perros: revisión narrativa

Endocannabinoid system and cannabidiol in the management of pain in dogs: a narrative review

Sistema endocanabinoide e canabidiol no manejo da dor em cães: uma revisão narrativa

DOI:

https://doi.org/10.15446/rcciquifa.v50n3.92935

Palavras-chave:

Caninos, Cannabis sativa, nocicepción. (es)

Downloads

Autores

  • Carmenza Janneth Benavides Melo Universidad de Nariño
  • María C. García-Cabrera Departamento de Sanidad Animal, Programa de Medicina Veterinaria, Facultad de Ciencias Pecuarias, Universidad de Nariño, Pasto
  • Olga T. Guerron-Morales Departamento de Sanidad Animal, Programa de Medicina Veterinaria, Facultad de Ciencias Pecuarias, Universidad de Nariño, Pasto
  • Juan M. Astaiza-Martínez Departamento de Sanidad Animal, Programa de Medicina Veterinaria, Facultad de Ciencias Pecuarias, Universidad de Nariño, Pasto
Introducción: la marihuana (Cannabis sativa L.)es una planta originaria de Asia cada vez más reconocida por su valor terapéutico en la medicina humana y veteri-naria.Contiene una gran cantidad de componentes entre los que destacan los fito-cannabinoides, de los cuales los más representativos son el delta-9-tetrahidrocanna-binol (THC) y Cannabidiol (CBD) que se acoplan respectivamente a los receptores CB1 y CB2 en el sistema endocannabinoide que es un sistema neurotransmisor entre células que regula varios procesos en los vertebrados como memoria, dolor, inflamación, apetito y procesos inmunológicos entre otros. Objetivo: realizar una síntesis narrativa del sistema endocannabinoide y cannabidiol en el manejo del dolor en perros, a partir de la búsqueda de publicaciones en bases de datos electrónica PubMed, NCBI, SciELO, Science Direct, Dialnet, Google y Google Académico. Resultados: el CBD es el principal cannabinoide utilizado en la terapia del manejo del dolor en perros por sus propiedades analgésicas y carencia de efectos psicoactivos.
Conclusión: se evidencia la necesidad de realizar más investigaciones con ensayos clínicos controlados sobre el uso terapéutico del cannabidiol, que tengan validez interna y externa, con poblaciones más significativas en la especie de interés.

Introduction: marijuana (Cannabis sativa L.) is a plant native to Asia that is increas-ingly recognized for its therapeutic value in human and veterinary medicine. It contains a large number of components among which the phytocannabinoids stand out, of which the most representative are delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) that are coupled respectively to the CB1 and CB2 receptors in the endocannabinoid system, which is a neurotransmitter system between cells that regulates various processes in vertebrates such as memory, pain, inflammation, appe-tite and immune processes among others. Aim: to carry out a narrative synthesis of the endocannabinoid and cannabidiol system in the management of pain in dogs, from the search of publications in electronic databases PubMed, NCBI, SciELO, Science Direct, Dialnet, Google and Google Scholar. Results: CBD is the main cannabinoid used in pain management therapy in dogs due to its analgesic proper-ties and lack of psychoactive effects. Conclusion: there is evidence of the need for more research with controlled clinical trials on the therapeutic use of cannabidiol, which have internal and external validity, with more significant populations in the species of interest.

Introdução: a maconha (Cannabis sativa L.) é uma planta nativa da Ásia que é cada vez mais reconhecida por seu valor terapêutico na medicina humana e veterinária. Ele contém muitos componentes entre os quais se destacam os fitocanabinóides, dos quais os mais representativos são delta-9-tetrahidrocanabinol (THC) e Canabidiol (CBD) que estão acoplados respectivamente aos receptores CB1 e CB2 no sistema endocanabinóide, que é um sistema neurotransmissor entre as células que regula vários processos nos vertebrados, como memória, dor, inflamação, apetite e processos imuno-lógicos, entre outros. Objetivo: realizar uma síntese narrativa do sistema endocana-binoide e canabidiol no manejo da dor em cães, a partir da busca de publicações nas bases de dados eletrônicas PubMed, NCBI, SciELO, Science Direct, Dialnet, Google e Google Scholar. Resultados: O CBD é o principal canabinoide utilizado na terapia de controle da dor em cães devido às suas propriedades analgésicas e ausência de efeitos psicoativos. Conclusão: há evidências da necessidade de mais pesquisas com ensaios clínicos controlados sobre o uso terapêutico do canabidiol, que tenham validade interna e externa, com populações mais significativas nas espécies de interesse.

Referências

J. Betancurt. Cannabis Medicinal En Veterinaria. - Modulación Del Sistema Endocannabinoide, URL: https://www.youtube.com/watch?v=9aNVZdJhO58&t=4054s, Octubre de 2020.

JR, Albaine-Pons. Biología de Cannabis Sativa (Marihuana) : efectos sobre animales de laboratorio, Ciencia y Sociedad , 10, 399 (1985). DOI: https://doi.org/10.22206/cys.1985.v10i3.pp399-411

Moiron AI. Sistema endocannabinoide: virtudes de una función poco conocida en el organismo animal. Selecciones veterinarias, URL: https://www.researchgate.net/publication/343639948%0APrevalencia, Octubre de 2020.

M. Hinojosa-Becerra M, I Marín-Gutierrez . El descubrimiento del cannabidiol, el principal componente del cannabis. Cannabis Magazine, URL: https://www.researchgate.net/publication/317237790%0AEl, Septiembre de 2020.

J. Osorio, H. Tangarife. Cannabis, Una Opción Terapéutica. Biosalud, 8,166 (2009).

S. Barbagallo, S. Finocchiaro. AM. Veterinary medical use of cannabis, cannabinoid receptors and endocannadinoid system in mammals. Lucr Stiint, URL: https://www.usab-tm.ro/USAMVBT_Revista_ro_1086.html. Septiembre de 2020.

F. Grotenhermen. Los cannabinoides y el sistema endocannabinoide. Cannabinoids, 1,1,10 (2006). DOI: https://doi.org/10.1159/000489141

A.A. Fernandes de Souza, A.F. Mendes da Silva, T.F. Silva, C.R. Oliveira. Cannabis sativa - Uso de fitocanabinóides para o tratamento da dor crôniCa. Brazilian J Nat Sci, URL: https://doi.org/10.31415/bjns.v2i1.30%0ACannabis. Abril de 2020. DOI: https://doi.org/10.31415/bjns.v2i1.30

C.A. Morales-Vallecilla. Bases para el manejo del dolor en perros y gatos, URL: http://bibliotecadigital.udea.edu.co/bitstream/10495/5567/8/MoralesVallecillaCarlos Arturo_2016_manejo_dolor_perros_gatos.pdf. Abril de 2020.

Z. Fišar. Phytocannabinoids and Endocannabinoids. Encycl Psychopharmacol, 2, 1, 51 (2009). DOI: https://doi.org/10.2174/1874473710902010051

L.K. Miller, L.A. Devi. The highs and lows of cannabinoid receptor expression in disease: Mechanisms and their therapeutic implications. Pharmacol Rev, 63, 3, 461 (2011). DOI: https://doi.org/10.1124/pr.110.003491

A.J. Hill, C.M. Williams, B.J. Whalley, G.J. Stephens. Phytocannabinoids as novel therapeutic agents in CNS disorders. Pharmacol Ther, 133, 1, 79 (2012). DOI: https://doi.org/10.1016/j.pharmthera.2011.09.002

L. Landa, A. Sulcova, P. Gbelec P. The use of cannabinoids in animals and therapeutic implications for veterinary medicine: A review. Vet Med (Praha), 61, 3, 111 (2016). DOI: https://doi.org/10.17221/8762-VETMED

R.R. Santisteban-Arenas, J.J. Betancurt. Perfiles fitocannabinoides en cannabis medicinal veterinario: ¿qué es y por qué debe importar? Remevet, URL: https://www.researchgate.net/publication/343836447%0APERFILES. Septiembre de 2020.

R.J. Silver. The Endocannabinoid System of Animals. Animals, 9, 9, 686 (2019). DOI: https://doi.org/10.3390/ani9090686

L.A. Matsuda, S.J. Lolait, M.J. Brownstein, A.C. TI. Young, Bonner. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature, 346, 6284, 561 (1990). DOI: https://doi.org/10.1038/346561a0

S. Munro, K.L. Thomas, M. Abu-Shaar. Molecular characterization of a peripheral receptor for cannabinoids. Nature, 365, 61 (1993). DOI: https://doi.org/10.1038/365061a0

R. Silver, J.A. Hartsel, K. Boyar, A. Pham, A. Makriyannis. Cannabis in Veterinary Medicine: Cannabinoid Therapies for Animals. In: Nutraceuticals in Veterinary Medicine, URL: https://www.researchgate.net/publication/333306722 Cannabis. Mayo de 2020. DOI: https://doi.org/10.1007/978-3-030-04624-8_10

W. Devane, L. Hanus, A. Breuer, R. Pertwee, L. Stevenson, G. Griffin, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 258, 5090, 1946 (1992). DOI: https://doi.org/10.1126/science.1470919

R. Mechoulam, S. Ben-Shabat, L. Hanus, M. Ligumsky, N.E. Kaminski, AR. Schatz, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol, 50, 1, 83 (1995). DOI: https://doi.org/10.1016/0006-2952(95)00109-D

R.G. Pertwee. Cannabinoid receptor ligands: Clinical and neuropharmacological considerations, relevant to future drug discovery and development. Expert Opin Investig Drugs, 9, 7, 1553 (2000). DOI: https://doi.org/10.1517/13543784.9.7.1553

N.M. Kogan, R. Mechoulam. The chemistry of endocannabinoids. J Endocrinol Invest, URL: https://www.researchgate.net/publication/7030692. Junio de 2020.

B. Basavarajappa. Neuropharmacology of the Endocannabinoid Signaling System-Molecular Mechanisms, Biological Actions and Synaptic Plasticity. Curr Neuropharmacol, 5, 2, 81 (2007). DOI: https://doi.org/10.2174/157015907780866910

J. Freundt-Revilla, K. Kegler, W. Baumgärtner, A. Tipold. Spatial distribution of cannabinoid receptor type 1 (CB1) in normal canine central and peripheral nervous system. PLoS One, URL: https://doi.org/10.1371/journal. pone.0181064. Octubre de 2020. DOI: https://doi.org/10.1371/journal.pone.0181064

C. Dall’Aglio, F. Mercati, L. Pascucci, C. Boiti, V. Pedini, P. Ceccarelli. Immunohistochemical localization of CB1 receptor in canine salivary glands. Vet Res Commun, 34, SUPPL.1, 9 (2010). DOI: https://doi.org/10.1007/s11259-010-9379-0

L. Campora, V. Miragliotta, E. Ricci, L. Cristino, D. Biol, V Di Marzo, et al. Cannabinoid receptor type 1 and 2 expression in the skin of healthy dogs and dogs with atopic dermatitis, Am J Vet Res, 73, 7 (2012). DOI: https://doi.org/10.2460/ajvr.73.7.988

F. Mercati, C. Dall’Aglio, L. Pascucci, C. Boiti, P. Ceccarelli. Identification of cannabinoid type 1 receptor in dog hair follicles. Acta Histochem, 114, 1, 68 (2012). DOI: https://doi.org/10.1016/j.acthis.2011.01.003

A. Pirone, C. Lenzi, A. Coli, E. Giannessi, M.R. Stornelli, V. Miragliotta. Preferential epithelial expression of type-1 cannabinoid receptor (CB1R) in the developing canine embryo. Springerplus, 4, 1 (2015). DOI: https://doi.org/10.1186/s40064-015-1616-0

A. Brutlag, H. Hommerding. Toxicology of Marijuana, Synthetic Cannabinoids, and Cannabidiol in Dogs and Cats. En: Veterinary Clinics of North America - Small Animal Practice, Vol. 48, USA, Elsevier Inc, 2018, p. 1087. DOI: https://doi.org/10.1016/j.cvsm.2018.07.008

R.G. Pertwee. Cannabinoid receptors and pain. Progress in Neurobiology. 63, 5, 569 (2001). DOI: https://doi.org/10.1016/S0301-0082(00)00031-9

R. Condie, A. Herring, W.S. Koh, M. Lee, N.E Kaminski. Cannabinoid inhibition of adenylate cyclase-mediated signal transduction and interleukin 2 (IL-2) expression in the murine T-cell line, EL4.IL-2. J Biol Chem, 271, 22, 13175 (1996) . DOI: https://doi.org/10.1074/jbc.271.22.13175

A.C. Howlett. Cannabinoid inhibition of adenylate cyclase: Relative activity of constituents and metabolites of marihuana. Neuropharmacology, 26, 5, 507 (1987). DOI: https://doi.org/10.1016/0028-3908(87)90035-9

A.C. Howlett. The cannabinoid receptors. Prostaglandins Other Lipid Mediat, 68–69, 619 (2002). DOI: https://doi.org/10.1016/S0090-6980(02)00060-6

J.P. Marcu, J.B. Schechter. Molecular Pharmacology of CB1 and CB2 Cannabinoid Receptors. En: Neuropathology of Drug Addictions and Substance Misuse. Elsevier Inc, USA, 2016, p. 713. DOI: https://doi.org/10.1016/B978-0-12-800213-1.00066-3

R.G. Pertwee. Pharmacological Actions of Cannabinoids. Handb Exp Pharmacol, 168, 1 (2005). DOI: https://doi.org/10.1007/3-540-26573-2_1

G. Griffin, E.J. Wray, Q. Tao, S.D. McAllister, W.K. Rorrer, M. Aung, et al. Evaluation of the cannabinoid CB2 receptor-selective antagonist, SR144528: Further evidence for cannabinoid CB2 receptor absence in the rat central nervous system. Eur J Pharmacol, 377, 117 (1999). DOI: https://doi.org/10.1016/S0014-2999(99)00402-1

M.W. Elmes, M. Kaczocha, W.T. Berger, K.N. Leung, B.P. Ralph, L. Wang, et al. Fatty acid-binding proteins (FABPs) are intracellular carriers for Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD). J Biol Chem, 290, 14, 8711 (2015). DOI: https://doi.org/10.1074/jbc.M114.618447

G. Bénard, F. Massa, N. Puente, J. Lourenço, L. Bellocchio, E. Soria-Gómez, et al. Mitochondrial CB 1 receptors regulate neuronal energy metabolism. Nat Neurosci, 15, 4, 558 (2012). DOI: https://doi.org/10.1038/nn.3053

T.H. Smith, L.C. Blume, A. Straiker, J.O. Cox, B.G. David, J.R. Secor McVoy, et al. Cannabinoid receptor-interacting protein 1a modulates CB1 receptor signaling and regulation. Mol Pharmacol, 87, 4, 747 (2015). DOI: https://doi.org/10.1124/mol.114.096495

M. Salazar, A. Carracedo, Í.J. Salanueva, S. Hernández-Tiedra, M. Lorente, A. Egia, et al. Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells. J Clin Invest, 119, 5, 1359 (2009). DOI: https://doi.org/10.1172/JCI37948

R.A. Ross. Anandamide and vanilloid TRPV1 receptors. Br J Pharmacol, 140, 5, 790 (2003). DOI: https://doi.org/10.1038/sj.bjp.0705467

S.P. Alexander, H.E. Benson, E. Faccenda, AJ. Pawson, JL. Sharman, M. Spedding, et al. The concise guide to pharmacology 2013/14: G protein-coupled receptors. Br Pharmacol Soc, 170, 8, 1459 (2013). DOI: https://doi.org/10.1111/bph.12445

M. Zubrzycki, A. Liebold, A. Janecka, M. Zubrzycka. A new face of endocannabinoids in pharmacotherapy. Part I: Protective role of endocannabinoids in hypertension and myocardial infarction. J Physiol Pharmacol, 65, 2, 171 (2014).

E. Samara, M. Bialer, R. Mechoulam. Pharmacokinetics of cannabidiol in dogs. Drug Metab Dispos, 16, 3, 469 (1988).

L.R. Bartner, S. McGrath, S. Rao , L.K. Hyatt, L.A. Wittenburg. Pharmacokinetics of cannabidiol administered by 3 delivery methods at 2 different dosages to healthy dogs. Can J Vet Res, 82, 178 (2018).

L.J. Gamble, .JM. Boesch, C.W. Frye, W.S. Schwark, S. Mann, L. Wolfe, et al. Pharmacokinetics, Safety, and Clinical Efficacy of Cannabidiol Treatment in Osteoarthritic Dogs. Front Vet Sci, 5, 1 (2018). DOI: https://doi.org/10.3389/fvets.2018.00165

A. Pons. Webinar cannabis en veterinaria. Dolor en perros y gatos. URL: https://www.youtube.com/watch?v=5Q-kteCzuDg&t=2221s. Septiembre de 2020.

C.S. Repetti, R.J. Girio, M. Friolani, S.M. Barbalho. Perspectives in veterinary medicine on the use of cannabinoids as complementary palliative therapy for pain in cancer patients. Cienc Rural, 49, 2, 1 (2019). DOI: https://doi.org/10.1590/0103-8478cr20180595

L.R. Kogan, R. Downing. The Use of Cannabidiol-Rich Hemp Oil Extract to Treat Canine Osteoarthritis-Related Pain : A Pilot Study. Am Holist Vet Med Assoc, 58(Spring), 35 (2020).

S.L. Casey, N. Atwal, C.W. Vaughan. Cannabis constituent synergy in a mouse neuropathic pain model, 158, 12, 2452 (2017). DOI: https://doi.org/10.1097/j.pain.0000000000001051

B. Costa, AE. Trovato, F. Comelli, G. Giagnoni, M. Colleoni. The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain. Eur J Pharmacol, 556, 1–3, 75 (2007). DOI: https://doi.org/10.1016/j.ejphar.2006.11.006

M.B. Escobar. "O potencial do canabidiol na terapêutica veterinária: revisão de literatura", Tesis de grado, Universidade Federal de Roraima, 2018, p. 59.

M.I. Antunes, K. Moreno, C.E. Grumadas. Avaliação e manejo da dor em cães e gatos com câncer - Revisão. Arq ciências veterinárias e Zool da unipar, 11, 2, 113 (2008).

M. Guevara, A. Gargiulo, P. Gargiulo, C. Calderón. Cannabis medicinal en mascotas ¿ Abriendo la caja de Pandora ? Revista veterinaria argentina, 35, 363, 1 (2018).

E. Russo, G.W. Guy. A tale of two cannabinoids: The therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses, 66, 2, 234 (2006). DOI: https://doi.org/10.1016/j.mehy.2005.08.026

M.A. Lessa, I.L. Cavalcanti, N.V. Figueiredo. Cannabinoid derivatives and the pharmacological management of pain. Rev Dor, 17, 1, 47 (2016). DOI: https://doi.org/10.5935/1806-0013.20160012

K.M. Honório, A. Arroio, A.B. Da Silva. Aspectos terapêuticos de compostos da planta Cannabis sativa. Quim Nova, 29, 2, 318 (2006). DOI: https://doi.org/10.1590/S0100-40422006000200024

E.B. Russo. Cannabinoids in the management of difficult to treat pain. Ther Clin Risk Manag, 4, 1, 245 (2008). DOI: https://doi.org/10.2147/TCRM.S1928

B.T. Simon, P.V. Steagall. The present and future of opioid analgesics in small animal practice. J Vet Pharmacol Ther, 40, 4, 315 (2017). DOI: https://doi.org/10.1111/jvp.12377

Como Citar

APA

Benavides Melo, C. J., García-Cabrera, M. C. ., Guerron-Morales, O. T. . e Astaiza-Martínez, J. M. . (2022). Sistema endocannabinoide y cannabidiol en el manejo del dolor en perros: revisión narrativa. Revista Colombiana de Ciencias Químico-Farmacéuticas, 50(3). https://doi.org/10.15446/rcciquifa.v50n3.92935

ACM

[1]
Benavides Melo, C.J., García-Cabrera, M.C. , Guerron-Morales, O.T. e Astaiza-Martínez, J.M. 2022. Sistema endocannabinoide y cannabidiol en el manejo del dolor en perros: revisión narrativa. Revista Colombiana de Ciencias Químico-Farmacéuticas. 50, 3 (fev. 2022). DOI:https://doi.org/10.15446/rcciquifa.v50n3.92935.

ACS

(1)
Benavides Melo, C. J.; García-Cabrera, M. C. .; Guerron-Morales, O. T. .; Astaiza-Martínez, J. M. . Sistema endocannabinoide y cannabidiol en el manejo del dolor en perros: revisión narrativa. Rev. Colomb. Cienc. Quím. Farm. 2022, 50.

ABNT

BENAVIDES MELO, C. J.; GARCÍA-CABRERA, M. C. .; GUERRON-MORALES, O. T. .; ASTAIZA-MARTÍNEZ, J. M. . Sistema endocannabinoide y cannabidiol en el manejo del dolor en perros: revisión narrativa. Revista Colombiana de Ciencias Químico-Farmacéuticas, [S. l.], v. 50, n. 3, 2022. DOI: 10.15446/rcciquifa.v50n3.92935. Disponível em: https://revistas.unal.edu.co/index.php/rccquifa/article/view/92935. Acesso em: 16 nov. 2024.

Chicago

Benavides Melo, Carmenza Janneth, María C. García-Cabrera, Olga T. Guerron-Morales, e Juan M. Astaiza-Martínez. 2022. “Sistema endocannabinoide y cannabidiol en el manejo del dolor en perros: revisión narrativa”. Revista Colombiana De Ciencias Químico-Farmacéuticas 50 (3). https://doi.org/10.15446/rcciquifa.v50n3.92935.

Harvard

Benavides Melo, C. J., García-Cabrera, M. C. ., Guerron-Morales, O. T. . e Astaiza-Martínez, J. M. . (2022) “Sistema endocannabinoide y cannabidiol en el manejo del dolor en perros: revisión narrativa”, Revista Colombiana de Ciencias Químico-Farmacéuticas, 50(3). doi: 10.15446/rcciquifa.v50n3.92935.

IEEE

[1]
C. J. Benavides Melo, M. C. . García-Cabrera, O. T. . Guerron-Morales, e J. M. . Astaiza-Martínez, “Sistema endocannabinoide y cannabidiol en el manejo del dolor en perros: revisión narrativa”, Rev. Colomb. Cienc. Quím. Farm., vol. 50, nº 3, fev. 2022.

MLA

Benavides Melo, C. J., M. C. . García-Cabrera, O. T. . Guerron-Morales, e J. M. . Astaiza-Martínez. “Sistema endocannabinoide y cannabidiol en el manejo del dolor en perros: revisión narrativa”. Revista Colombiana de Ciencias Químico-Farmacéuticas, vol. 50, nº 3, fevereiro de 2022, doi:10.15446/rcciquifa.v50n3.92935.

Turabian

Benavides Melo, Carmenza Janneth, María C. García-Cabrera, Olga T. Guerron-Morales, e Juan M. Astaiza-Martínez. “Sistema endocannabinoide y cannabidiol en el manejo del dolor en perros: revisión narrativa”. Revista Colombiana de Ciencias Químico-Farmacéuticas 50, no. 3 (fevereiro 4, 2022). Acessado novembro 16, 2024. https://revistas.unal.edu.co/index.php/rccquifa/article/view/92935.

Vancouver

1.
Benavides Melo CJ, García-Cabrera MC, Guerron-Morales OT, Astaiza-Martínez JM. Sistema endocannabinoide y cannabidiol en el manejo del dolor en perros: revisión narrativa. Rev. Colomb. Cienc. Quím. Farm. [Internet]. 4º de fevereiro de 2022 [citado 16º de novembro de 2024];50(3). Disponível em: https://revistas.unal.edu.co/index.php/rccquifa/article/view/92935

Baixar Citação

CrossRef Cited-by

CrossRef citations0

Dimensions

PlumX

Acessos à página de resumo

3515

Downloads

Não há dados estatísticos.

Licença

Creative Commons License
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.

El Departamento de Farmacia de la Facultad de Ciencias de la Universidad Nacional de Colombia  autoriza la fotocopia de artículos y textos para fines de uso académico o interno de las instituciones citando la fuente. Las ideas emitidas por los autores son responsabilidad expresa de estos y no de la revista.

Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons de Atribución 4.0 aprobada en Colombia. Consulte la normativa en: http://co.creativecommons.org/?page_id=13